Finance

Beta
Ask
Lists
BCRX:NASDAQ
BioCryst Pharmaceuticals Inc
$9.14
+1.67%
(+0.15) 1D
$9.11
-0.30% (-0.028)
After hours
Closed: Jun 22, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BCRX...
Open
$9.04
High
$9.34
Low
$8.91
Mkt. cap
2.32B
Avg. vol.
4.66M
Volume
7.41M
52-wk high
$10.32
52-wk low
$6.00
EPS
-$1.78
Beta
0.57
Shares outstanding
254.16M
No. of employees
435
Open
$9.04
High
$9.34
Low
$8.91
Mkt. cap
2.32B
Avg. vol.
4.66M
Volume
7.41M
52-wk high
$10.32
52-wk low
$6.00
EPS
-$1.78
Beta
0.57
Shares outstanding
254.16M
No. of employees
435
News stories
From sources across the web
Profile
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China. Wikipedia
About BioCryst Pharmaceuticals Inc
CEOJon P. Stonehouse
Employees435
Founded1986
HeadquartersDurham, North Carolina, United States
SectorBiotechnology
Websitebiocryst.com
Analyst Ratings
Based on 7 analysts giving stock ratings to BCRX in the past 3 months
Strong Buy
Buy
7
Hold
0
Sell
0
12 month forecast
Based on 7 Wall Street analysts offering 12 month price targets for BCRX in the last 3 months.
Highest
Current $9.14
$32.00 (+250.11%)
Average
$23.33 (+155.25%)
Lowest
$13.00 (+42.23%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Laura Chico
Wedbush
Buy
Maintained
$21.00
+129.8%
05/07/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$28.00
+206.3%
05/07/2026
Andrew Fein
H.C. Wainwright
Buy
Maintained
$32.00
+250.1%
05/07/2026
Serge Belanger
Needham
Buy
Maintained
$16.00
+75.1%
05/06/2026
Stacy Ku
TD Cowen
Buy
Maintained
$30.00
+228.2%
05/06/2026
Brian Abrahams
RBC Capital
Buy
Maintained
$13.00
+42.2%
05/06/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
-
-
04/16/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Initiated
$17.00
+86%
02/18/2026
Last report
May 6, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$0.14 / $0.11
+27.68%beat
Revenue / Est. (USD)
156.41M / 151.66M
+3.13%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
163.35M
159.40M
406.56M
156.41M
Cost of goods sold
46.18M
46.79M
48.35M
65.70M
Cost of revenue
46.18M
46.79M
48.35M
65.70M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
87.38M
83.01M
91.51M
94.55M
Operating expense
87.38M
83.01M
91.51M
94.55M
Total operating expenses
133.57M
129.80M
139.86M
160.25M
Operating income
29.79M
29.59M
266.70M
-3.84M
Other non operating income
-
2.67M
5.86M
-1.46M
EBT including unusual items
6.49M
12.13M
248.02M
-720.81M
EBT excluding unusual items
10.66M
14.87M
261.19M
-23.05M
Income tax expense
1.40M
-769.00K
2.17M
1.00M
Effective tax rate
21.60%
-6.34%
0.88%
-0.14%
Other operating expenses
-
-
-
-
Net income
5.08M
12.90M
245.84M
-721.81M
Net profit margin
3.11%
8.09%
60.47%
-461.48%
Earnings per share
0.04
0.16
0.21
0.14
Interest and investment income
2.52M
2.24M
2.89M
2.26M
Interest expense
-21.58M
-19.66M
-14.14M
-19.78M
Net interest expenses
-19.07M
-17.42M
-11.24M
-17.52M
Depreciation and amortization charges
-
-
-
-
EBITDA
30.12M
31.56M
267.55M
-2.78M
Gain or loss from assets sale
-
-550.00K
-3.57M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer